Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anderson-Fabry disease in Austria.

Matthias Lorenz1, Anna-Christina Hauser, Margot Püspök-Schwarz

  • 1Division of Nephrology and Dialysis, Department of Medicine III, University of Vienna, Vienna. Matthias.Lorenz@akh-wien.ac.at

Wiener Klinische Wochenschrift
|June 5, 2003
PubMed
Summary

Fabry disease is a genetic disorder causing glycosphingolipid buildup. Enzyme replacement therapy shows promise for managing symptoms and disease progression in affected families.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional Characterization of a Novel Intronic Complement Factor I Variant in Factor I Deficiency and Atypical Hemolytic Uremic Syndrome.

Kidney international reports·2026
Same author

The Dry-Weight Dilemma: Survey Results Based on a Qualitative Interview Study on Fluid Overload in Hemodialysis.

Kidney medicine·2026
Same author

Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial.

ESC heart failure·2026
Same author

Longitudinal Adipokine and Lipid Profiles in Fabry Disease.

Journal of clinical medicine·2026
Same author

Impact of SGLT2 inhibitors in patients with Fabry disease.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study.

EClinicalMedicine·2026

Area of Science:

  • Genetics and Metabolic Disorders
  • Lysosomal Storage Diseases

Background:

  • Fabry disease is an X-linked inherited disorder of glycosphingolipid metabolism.
  • Deficiency of alpha-galactosidase A causes glycosphingolipid accumulation in lysosomes, particularly in blood vessel cells.

Observation:

  • Clinical manifestations include extremity pain, angiokeratoma, vision issues, and hypohidrosis.
  • Progressive disease involves renal, cardiac, cerebral, and vascular complications, often leading to organ damage.
  • Female carriers can also exhibit Fabry disease symptoms.

Findings:

  • The analysis focuses on five Austrian families with Fabry disease.
  • Discusses enzyme replacement therapy (ERT) indications for patients on renal replacement therapy.

Related Experiment Videos

Implications:

  • Enzyme replacement therapy offers potential for controlling or reversing Fabry disease progression.
  • Highlights the importance of nephrologists in managing Fabry disease patients.
  • Emphasizes the need for timely diagnosis and treatment, including for female carriers.